Supranuclear Palsy, Progressive
"Supranuclear Palsy, Progressive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
MeSH Number(s)
C10.228.140.079.882
C10.228.662.700
C10.292.562.750.500
C10.574.945.500
C10.597.622.447.690
C11.590.472.500
C23.888.592.636.447.690
Concept/Terms
Supranuclear Palsy, Progressive- Supranuclear Palsy, Progressive
- Progressive Supranuclear Palsies
- Progressive Supranuclear Palsy
- Supranuclear Palsies, Progressive
- Steele-Richardson-Olszewski Disease
- Steele Richardson Olszewski Disease
- Ophthalmoplegia, Progressive Supranuclear
- Ophthalmoplegias, Progressive Supranuclear
- Progressive Supranuclear Ophthalmoplegias
- Supranuclear Ophthalmoplegia, Progressive
- Supranuclear Ophthalmoplegias, Progressive
- Progressive Supranuclear Ophthalmoplegia
- Steele-Richardson-Olszewski Syndrome
- Steele Richardson Olszewski Syndrome
- Syndrome, Steele-Richardson-Olszewski
- Palsy, Progressive Supranuclear
Below are MeSH descriptors whose meaning is more general than "Supranuclear Palsy, Progressive".
Below are MeSH descriptors whose meaning is more specific than "Supranuclear Palsy, Progressive".
This graph shows the total number of publications written about "Supranuclear Palsy, Progressive" by people in Harvard Catalyst Profiles by year, and whether "Supranuclear Palsy, Progressive" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 1 | 3 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 2 | 5 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 4 | 2 | 6 |
| 2022 | 3 | 0 | 3 |
| 2023 | 3 | 0 | 3 |
Below are the most recent publications written about "Supranuclear Palsy, Progressive" by people in Profiles.
-
[18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration. J Nucl Med. 2023 12 01; 64(12):1980-1989.
-
Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome. JAMA Neurol. 2023 05 01; 80(5):495-505.
-
Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. J Neuropathol Exp Neurol. 2023 04 20; 82(5):438-451.
-
Toward More Accessible Fully Automated 3D Volumetric MRI Decision Trees for the Differential Diagnosis of Multiple System Atrophy, Related Disorders, and Age-Matched Healthy Subjects. Cerebellum. 2023 Dec; 22(6):1098-1108.
-
Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration. Neurology. 2022 Sep 13; 99(11):e1154-e1167.
-
LC3/FtMt Colocalization Patterns Reveal the Progression of FtMt Accumulation in Nigral Neurons of Patients with Progressive Supranuclear Palsy. Int J Mol Sci. 2022 Jan 04; 23(1).
-
Pain in neurodegenerative diseases with atypical parkinsonism: a systematic review on prevalence, clinical presentation, and findings from experimental studies. J Integr Neurosci. 2021 Dec 30; 20(4):1067-1078.
-
Clinical Correlation Between Vertical Gaze Palsy and Midbrain Volume in Progressive Supranuclear Palsy. J Neuroophthalmol. 2022 06 01; 42(2):246-250.
-
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021 08; 27(8):1451-1457.
-
Case 20-2021: A 69-Year-Old Man with Ataxia. N Engl J Med. 2021 Jul 08; 385(2):165-175.